Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec;59(4):761-764.
doi: 10.20471/acc.2020.59.04.25.

OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT

Mirjana Pavlović  1 , Robert Šeparović  1 , Tajana Silovski  1 , Ana Tečić Vuger  1 , Andreja Jurić  1
Affiliations
Case Reports

OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT

Mirjana Pavlović et al. Acta Clin Croat. 2020 Dec.

Abstract

Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted in patient death in more than half of the reported cases. The precise pathophysiological mechanism of this phenomenon has not been clarified yet. Analysis of the reported cases strongly suggests that early diagnosis and immediate corticosteroid treatment are crucial for better prognosis. Here we report a case of pulmonary fibrosis related to the FOLFOX regimen in a patient with early colorectal carcinoma.

Keywords: Colon cancer; Interstitial lung disease; Oxaliplatin; Pulmonary fibrosis; Side effects.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Computed tomography scan performed after 6 cycles of adjuvant FOLFOX therapy showing normal finding.
Fig. 2
Fig. 2
Computed tomography scan performed after 11 cycles of FOLFOX therapy showing interstitial lung disease with signs of incipient pulmonary fibrosis.
Fig. 3
Fig. 3
Computed tomography scan performed two months after initiation of corticosteroid therapy showing regression of pulmonary interstitial infiltrates.
See this image and copyright information in PMC

References

    1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000. August;18(16):2938–47. 10.1200/JCO.2000.18.16.2938 - DOI - PubMed
    1. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol. 2003. August 1;21(15):2904–11. 10.1200/JCO.2003.11.045 - DOI - PubMed
    1. Homma T, Kurokawa M, Yamamoto Y, Matsukura S, Ieki K, Suzuki S. Oxaliplatin-induced lung injury with allergic reaction. Chin J Cancer Res. 2011. September;23(3):232–5. 10.1007/s11670-011-0232-y - DOI - PMC - PubMed
    1. Moskovitz M, Wollner M, Haim N. Oxaliplatin-induced pulmonary toxicity in gastrointestinal malignancies: two case reports and review of the literature. Case Rep Oncol Med. 2015;2015:341064. 10.1155/2015/341064 - DOI - PMC - PubMed
    1. Kinnula VL, Vuorinen K, Ilumets H, Rytila P, Myllarniemi M. Thiol proteins, redox modulation and parenchymal lung disease. Curr Med Chem. 2007;14:213–22. 10.2174/092986707779313345 - DOI - PubMed

Publication types

LinkOut - more resources